无症状重度主动脉瓣狭窄伴左心室肥厚患者的主动脉瓣置换与死亡率
该研究基于12家医院1 232 492份超声报告,经自然语言处理筛选并人工确认607例无症状、正常血流、LVEF≥55%的重度主动脉瓣狭窄伴左心室肥厚患者。采用Cox比例风险模型(AVR为时变协变量)分析显示,AVR与死亡率降低相关(HR 0.37;95%CI 0.25-0.55,P<0.0001)。
要点
- 无症状重度AS伴LVH且LVEF≥55%患者中,AVR与死亡率降低独立相关。
- LVH比心肌纤维化更易评估,或可作为优先干预的标记。
- 结果提示对无症状但伴LVH的正常LVEF患者可考虑更积极的AVR。
核心结论
- 在无症状重度主动脉瓣狭窄、LVEF保留且伴左心室肥厚的患者中,主动脉瓣置换与死亡率降低相关。
研究设计与样本
- 多中心回顾性队列研究,初始筛查12家医院1 232 492份超声报告,经自然语言处理及医师病历复核确认607例无症状、正常血流、LVEF≥55%的重度AS伴LVH患者。
- 采用Cox比例风险模型,以索引超声心动图时间为零时点,将AVR作为时变协变量分析其与死亡率的关联。
主要发现
- 调整后并考虑AVR的时间依赖性,AVR与死亡率降低相关(HR 0.37;95%CI 0.25-0.55,P<0.0001)。
临床怎么用
- 对于无症状重度AS伴LVH且LVEF≥55%的患者,LVH可作为优先考虑AVR的参考指标。
- 在指南对无症状重度AS干预适应症扩大的背景下,LVH易于评估,有助于识别需优先干预的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Indications for aortic valve replacement (AVR) in severe asymptomatic aortic stenosis (AS) differ for individuals with normal versus low or decreasing left ventricular ejection fraction (LVEF). Conceptually, the development of left ventricular hypertrophy (LVH) could also indicate ventricular injury and potential need for earlier AVR. METHODS: Initially, 1 232 492 echocardiography reports from 12 hospitals were identified; then previously validated, open-source natural language processing modules were applied to identify aortic gradients, LVEF, and the presence of LVH. These reports were linked to mortality data, key comorbidities, and date of any AVR. We then performed physician chart reviews, identified asymptomatic individuals with normal flow severe AS, LVEF ≥ 55%, and LVH, and confirmed key clinical data manually. To assess the association between AVR and mortality, Cox proportional hazards models considering treatment status (i.e., AVR or not considered as a time-dependent covariate) were used with the index echocardiogram as time zero. RESULTS: After application of eligibility criteria, 607 unique, confirmed asymptomatic individuals remained for the primary analysis. After adjustment, and accounting for the time-dependence of AVR, AVR was associated with reduced mortality (hazard ratio 0.37; 95% confidence interval 0.25-0.55, P < 0.0001). CONCLUSIONS: AVR was associated with reduced mortality for patients with severe asymptomatic AS, preserved LVEF, and LVH. This is the largest known analysis of aortic valve replacement outcomes in individuals with severe aortic stenosis and left ventricular hypertrophy. As clinical guidelines for intervention in asymptomatic severe aortic stenosis expand, left ventricular hypertrophy is easier to assess than myocardial fibrosis and may be a useful marker for patients who need to be prioritized. These results raise the potential of more proactive AVR in individuals with LVH, even among asymptomatic individuals with normal LVEF.
引用
- Wasfy JH, Etiwy M, Zhao Y, et al. Aortic valve replacement and mortality in asymptomatic individuals with severe aortic stenosis and left ventricular hypertrophy. Eur J Cardiothorac Surg. 2025. PMID: 40889283. doi:10.1093/ejcts/ezaf211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。